“Translational Regenerative Medicine market set to grow to $76bn by 2023” says new Visiongain report

07 February 2019
Pharma

Visiongain has launched a new pharma report Translational Regenerative Medicine Market Forecast 2019-2029: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

The high potential earning for companies from products aimed at repairing organs and tissues has led to an increase in the attention given to regenerative medicine research. Regenerative medicine (RM) is viewed as possessing the ability to provide therapeutic products targeted at multiple disease classes, such as cardiovascular, dermatological, and orthopaedic conditions. Developments in stem cell therapies and tissue engineering in particular may catalyse rapid growth in the translational regenerative medicine market over the next decade and beyond.

The lead analyst of the report commented "Regenerative medicine has become an area of competition between many national governments, particularly in Asia-Pacific. Partly, this is due to a desire to demonstrate excellence in national biotechnology industries, especially in emerging markets wanting to show progress in moving towards a knowledge-based economy. Governments are also concerned about obtaining a share in the global healthcare market of the future, when TRM products may be expected to overtake other types of treatment in the field of medicine, delivering both improved clinical outcomes and cost savings."

Leading companies featured in the report include Athersys, Inc., Avita Medical, AxoGen, Inc., MEDIPOST Co., Ltd., NuVasive, Astellas Pharma, Organogenesis Holdings Inc., Osiris Therapeutics, Inc. and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“In 2017, the Top 5 Vaccines Manufacturers held 76% of the Global Vaccines Market” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs.

12 February 2019

Read

“Translational Regenerative Medicine market set to grow to $76bn by 2023” says new Visiongain report

Regenerative medicine has become an area of competition between many national governments, particularly in Asia-Pacific.

07 February 2019

Read

“Global Pre-Filled Syringes market set to grow to $19bn by 2024” says new Visiongain report

The market is expected to grow strongly driven by numerous trends in the overall pharmaceutical market, such as more self-administration of medicines, the development of biological drugs and biosimilars, and the increasing burden of chronic diseases such as diabetes and high cholesterol.

31 January 2019

Read

“30% of the Top Generic Drug Producers are in the ROW region” says new Visiongain report

This report ranks the world’s top 50 generic drug manufacturers according to their generic drug revenues in 2017.

31 January 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1